CJC-1295 / Ipamorelin

CJC-1295 is a synthetic analogue of GHRH, specifically a modified version of GHRH (1-29). CJC-1295 acts at pituitary GHRH receptors (GHRHR) to stimulate growth hormone secretion via Gs protein coupling and adenylate cyclase activation. Ipamorelin is a pentapeptide (711.9 g/mol) and a highly selective agonist at GHSR-1a — the canonical ghrelin receptor. The combination reflects a dual-mechanism hypothesis: simultaneous activation of GHRH receptor and ghrelin receptor produces synergistic GH secretion exceeding what either compound achieves alone.

Research applications center on dual-mechanism pharmacological probes for the hypothalamic-pituitary somatotropic axis. Comparative pharmacology studies examining CJC-1295 and Ipamorelin individually versus in combination provide experimental data on receptor crosstalk and synergy dynamics. Sleep physiology research represents a distinct GHS research territory, as Ipamorelin's selectivity for GHSR-1a without significant cortisol or prolactin co-stimulation has made it a tool compound in preclinical studies.

Each component is synthesized separately via SPPS and subjected to independent third-party HPLC analysis before co-lyophilization. This component-first quality architecture ensures purity is verified at the individual compound level. We guarantee ≥99% purity for each component individually. The certifying laboratory's name, HPLC methodology, and testing date for each component are documented on the Certificate of Analysis.

This product is strictly for research and laboratory use only. It is not approved by the FDA or any global regulatory body for human consumption, veterinary use, or therapeutic application. The purchaser assumes all responsibility for the proper handling, storage, and application of this compound. It must only be handled by qualified professionals in a controlled laboratory setting. By purchasing this product, you agree to abide by all local and international laws regarding the use of research chemicals.